Ionis Pharmaceuticals Dirección
Dirección controles de criterios 2/4
El CEO de Ionis Pharmaceuticals es Brett Monia , nombrado en Jan 2020, tiene una permanencia de 4.83 años. compensación anual total es $12.50M, compuesta por 7.7% salario y 92.3% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.11% de las acciones de la empresa, por valor de $6.74M. La antigüedad media del equipo directivo y de la junta directiva es de 4.8 años y 8.5 años, respectivamente.
Información clave
Brett Monia
Chief Executive Officer (CEO)
US$12.5m
Compensación total
Porcentaje del salario del CEO | 7.7% |
Permanencia del CEO | 4.8yrs |
Participación del CEO | 0.1% |
Permanencia media de la dirección | 4.8yrs |
Promedio de permanencia en la Junta Directiva | 8.5yrs |
Actualizaciones recientes de la dirección
Recent updates
Ionis Pharmaceuticals: Catalysts Due In 2025/2026 Are Extremely Compelling
Oct 23There Is A Reason Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) Price Is Undemanding
Aug 24Ionis Pharmaceuticals: Harnessing RNA-Targeted Therapies For Long-Term Shareholder Value
Aug 11Health Check: How Prudently Does Ionis Pharmaceuticals (NASDAQ:IONS) Use Debt?
Jul 28Ionis: Tough Run For Share Price Belies Multiple Reasons For Optimism
May 28Analysts Have Made A Financial Statement On Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) First-Quarter Report
May 09Lacklustre Performance Is Driving Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) Low P/S
Apr 14Is Ionis Pharmaceuticals (NASDAQ:IONS) Using Debt Sensibly?
Mar 18Ionis Pharmaceuticals 2023 Earnings Review: Short-Term Pain, Long-Term Gain
Feb 23Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Investors Are Less Pessimistic Than Expected
Dec 28Ionis Pharmaceuticals (NASDAQ:IONS) Has Debt But No Earnings; Should You Worry?
Dec 07A Look At The Intrinsic Value Of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)
Nov 16Ionis Pharmaceuticals (NASDAQ:IONS) Has Debt But No Earnings; Should You Worry?
Aug 03Is Ionis Pharmaceuticals (NASDAQ:IONS) Using Debt Sensibly?
May 05Does Ionis Pharmaceuticals (NASDAQ:IONS) Have A Healthy Balance Sheet?
Jan 20Ionis Pharmaceuticals Looks Good For The Long Term
Oct 19Ionis plans for new manufacturing site in California to support pipeline
Oct 13Ionis: 2 Drug Advancements With Potential Firsts
Aug 29Ionis Pharmaceuticals Q2 2022 Earnings Preview
Aug 08Ionis Pharmaceuticals (NASDAQ:IONS) Could Easily Take On More Debt
Aug 08Análisis de compensación del CEO
Fecha | Compensación total | Salario | Ingresos de la empresa |
---|---|---|---|
Jun 30 2024 | n/a | n/a | -US$366m |
Mar 31 2024 | n/a | n/a | -US$385m |
Dec 31 2023 | US$13m | US$961k | -US$366m |
Sep 30 2023 | n/a | n/a | -US$409m |
Jun 30 2023 | n/a | n/a | -US$309m |
Mar 31 2023 | n/a | n/a | -US$329m |
Dec 31 2022 | US$7m | US$825k | -US$270m |
Sep 30 2022 | n/a | n/a | US$7m |
Jun 30 2022 | n/a | n/a | -US$28m |
Mar 31 2022 | n/a | n/a | -US$4m |
Dec 31 2021 | US$13m | US$800k | -US$29m |
Sep 30 2021 | n/a | n/a | -US$608m |
Jun 30 2021 | n/a | n/a | -US$550m |
Mar 31 2021 | n/a | n/a | -US$495m |
Dec 31 2020 | US$11m | US$700k | -US$444m |
Sep 30 2020 | n/a | n/a | US$94m |
Jun 30 2020 | n/a | n/a | US$145m |
Mar 31 2020 | n/a | n/a | US$169m |
Dec 31 2019 | US$7m | US$528k | US$281m |
Sep 30 2019 | n/a | n/a | US$433m |
Jun 30 2019 | n/a | n/a | US$402m |
Mar 31 2019 | n/a | n/a | US$366m |
Dec 31 2018 | US$4m | US$508k | US$277m |
Sep 30 2018 | n/a | n/a | -US$41m |
Jun 30 2018 | n/a | n/a | -US$38m |
Mar 31 2018 | n/a | n/a | US$9m |
Dec 31 2017 | US$2m | US$443k | US$19m |
Compensación vs. Mercado: La compensación total de Brett($USD12.50M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD8.06M).
Compensación vs. Ingresos: La compensación de Brett ha aumentado mientras la empresa no es rentable.
CEO
Brett Monia (63 yo)
4.8yrs
Permanencia
US$12,500,023
Compensación
Dr. Brett P. Monia, Ph.D. is a Founder of Ionis Pharmaceuticals, Inc. in 1989 and has been Chief Executive Officer since January 2020. He has extensive experience across a range of therapeutic areas, inclu...
Equipo directivo
Nombre | Posición | Permanencia | Compensación | Propiedad |
---|---|---|---|---|
Founder | 4.8yrs | US$12.50m | 0.11% $ 6.7m | |
Executive VP of Finance & CFO | 11.8yrs | US$2.89m | 0.059% $ 3.6m | |
Director | 6.8yrs | US$538.04k | 0.055% $ 3.4m | |
Executive VP & Chief Development Officer | 16.3yrs | US$2.56m | 0.054% $ 3.3m | |
Executive Vice President of Research | 4.8yrs | US$2.56m | 0.022% $ 1.4m | |
Chief Accounting Officer & Senior VP | 4.8yrs | sin datos | sin datos | |
Executive VP & Chief Scientific Officer | 4.8yrs | US$958.87k | 0.051% $ 3.1m | |
Senior Vice President of Investor Relations | no data | sin datos | sin datos | |
Executive VP | 11.8yrs | US$3.92m | 0.031% $ 1.9m | |
Vice President of Corporate Communications | less than a year | sin datos | sin datos | |
Senior Vice President of Human Resources | 4.8yrs | sin datos | 0.0050% $ 306.5k | |
Scientific Advisor | 3.4yrs | US$2.28m | sin datos |
4.8yrs
Permanencia media
64.5yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de IONS se considera experimentado (4.8 años antigüedad media).
Miembros de la Junta
Nombre | Posición | Permanencia | Compensación | Propiedad |
---|---|---|---|---|
Founder | 5.7yrs | US$12.50m | 0.11% $ 6.7m | |
Director | 24.2yrs | US$538.04k | 0.055% $ 3.4m | |
Independent Director | 5.4yrs | US$540.04k | 0.027% $ 1.6m | |
Independent Director | 18.9yrs | US$542.04k | 0.010% $ 637.4k | |
Lead Independent Director | 30.8yrs | US$598.04k | 0.084% $ 5.1m | |
Independent Director | 6.2yrs | US$528.04k | 0.020% $ 1.2m | |
Independent Director | 22.5yrs | US$548.04k | 0.097% $ 5.9m | |
Independent Chairman of the Board | 10.8yrs | US$568.04k | 0.029% $ 1.8m | |
Independent Director | 3.4yrs | US$530.04k | 0.010% $ 609.3k | |
Independent Director | less than a year | US$363.05k | sin datos |
8.5yrs
Permanencia media
70yo
Promedio de edad
Junta con experiencia: La junta directiva de IONS se considera experimentada (8.5 años de antigüedad promedio).